Abstract
In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.
| Original language | English |
|---|---|
| Journal | Acta oncologica |
| Volume | 27 |
| Issue number | 5 |
| Pages (from-to) | 521-5 |
| Number of pages | 5 |
| ISSN | 0284-186X |
| Publication status | Published - 1988 |
Keywords
- Administration, Oral
- Adult
- Aged
- Drug Evaluation
- Female
- Humans
- Idarubicin
- Male
- Middle Aged
- Neoplasms